Global Histone Deacetylase 1 Market Report (2025–2036)
Market Overview
The global HDAC1 market was valued at USD xxxx million in 2025 and is projected to reach USD xxxx million by 2036, growing at a CAGR of xx%. HDAC1 inhibitors are emerging as promising therapeutic agents in oncology, neurology, and rare diseases due to their role in epigenetic regulation. Increasing R&D investments, expanding clinical pipelines, and growing interest in targeted therapies are fueling market growth.
Impact of COVID-19
The pandemic disrupted clinical trials and slowed drug development in 2020. However, renewed focus on oncology and immunology research post-pandemic has accelerated interest in HDAC1 inhibitors, particularly in combination therapies and precision medicine.
Segmentation Analysis
By Type
· RCY-1305
· HG-3001
· CS-3158
· ACY-957
· ST-3595
· Other Pipeline Candidates
By Application
· Alopecia
· Endometrial Cancer
· Myelofibrosis
· Neurology (neurodegenerative diseases)
· Skin Cancer
· Hematological Malignancies
· Others
By Therapy Class
· Monotherapy HDAC1 Inhibitors
· Combination Therapies (HDAC1 + Immunotherapy/Targeted Therapy)
· Research & Development Applications
Regional Analysis
· North America: Leading market due to strong R&D infrastructure, high clinical trial activity, and presence of major biotech firms.
· Europe: Growth supported by government-funded research and strong pharmaceutical industry.
· Asia-Pacific: Fastest-growing region, with expanding biotech hubs in China, India, and Japan.
· South America: Moderate growth, with Brazil leading in oncology research collaborations.
· Middle East & Africa: Emerging opportunities with increasing healthcare investments and demand for advanced therapies.
Key Players
· 4SC AG
· Acetylon Pharmaceuticals Inc.
· Chipscreen Biosciences Ltd.
· Curis Inc.
· GlaxoSmithKline Plc
· HitGen Ltd.
· IRBM Science Park SpA
· Italfarmaco S.p.A.
· MEI Pharma Inc.
· Merck & Co. Inc.
· Mirati Therapeutics Inc.
· Oncolys BioPharma Inc.
· Sigma-Tau S.p.A.
· Syndax Pharmaceuticals Inc.
· TetraLogic Pharmaceuticals
· Novartis AG
· Bristol Myers Squibb
· AbbVie Inc.
· Eli Lilly and Company
· AstraZeneca Plc
Porter’s Five Forces
· Threat of New Entrants: Low, due to high R&D costs and regulatory barriers.
· Bargaining Power of Suppliers: Moderate, with reliance on specialized biologics and reagents.
· Bargaining Power of Buyers: High, as hospitals and research institutes demand cost-effective therapies.
· Threat of Substitutes: Moderate, with alternative epigenetic and immunotherapy approaches.
· Industry Rivalry: High, with global pharmaceutical companies competing on innovation and clinical trial success.
SWOT Analysis
Strengths: Strong potential in oncology and neurology, growing clinical pipeline. Weaknesses: High development costs, long regulatory timelines. Opportunities: Expansion in emerging markets, novel biologics and antibody engineering. Threats: Competition from alternative immunotherapy targets, supply chain risks.
Trend Analysis
· Rising focus on epigenetic therapies in oncology.
· Increasing adoption of HDAC1 inhibitors in combination therapies.
· Growth in precision medicine and biomarker-driven treatments.
· Expansion of collaborations between biotech firms and academic research institutes.
Drivers & Challenges
Drivers:
· Rising prevalence of cancer and neurodegenerative diseases.
· Increasing R&D investments in epigenetics.
· Advancements in drug discovery technologies.
Challenges:
· High cost of drug development.
· Stringent regulatory approval processes.
· Limited awareness in developing regions.
Value Chain Analysis
· Raw Material Suppliers (biologics, reagents) → Biotech/Pharma Manufacturers → Clinical Trial Networks → Hospitals/Research Institutes → End Patients
· Strategic partnerships and licensing agreements are critical for accelerating drug development and commercialization.
Recommendations for Stakeholders
· Manufacturers: Invest in combination therapies and expand clinical trial pipelines.
· Healthcare Providers: Integrate HDAC1 therapies into oncology and neurology treatment protocols.
· Investors: Focus on North America and Asia-Pacific for high growth potential.
· Policy Makers: Support epigenetics research funding and streamline regulatory approvals.
1. Market Overview of Histone Deacetylase 1
1.1 Histone Deacetylase 1 Market Overview
1.1.1 Histone Deacetylase 1 Product Scope
1.1.2 Market Status and Outlook
1.2 Histone Deacetylase 1 Market Size by Regions:
1.3 Histone Deacetylase 1 Historic Market Size by Regions
1.4 Histone Deacetylase 1 Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Histone Deacetylase 1 Sales Market by Type
2.1 Global Histone Deacetylase 1 Historic Market Size by Type
2.2 Global Histone Deacetylase 1 Forecasted Market Size by Type
2.3 RCY-1305
2.4 HG-3001
2.5 CS-3158
2.6 ACY-957
2.7 ST-3595
2.8 Others
3. Covid-19 Impact Histone Deacetylase 1 Sales Market by Application
3.1 Global Histone Deacetylase 1 Historic Market Size by Application
3.2 Global Histone Deacetylase 1 Forecasted Market Size by Application
3.3 Alopecia
3.4 Endometrial Cancer
3.5 Myelofibrosis
3.6 Neurology
3.7 Skin Cancer
3.8 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Histone Deacetylase 1 Production Capacity Market Share by Manufacturers
4.2 Global Histone Deacetylase 1 Revenue Market Share by Manufacturers
4.3 Global Histone Deacetylase 1 Average Price by Manufacturers
5. Company Profiles and Key Figures in Histone Deacetylase 1 Business
5.1 4SC AG
5.1.1 4SC AG Company Profile
5.1.2 4SC AG Histone Deacetylase 1 Product Specification
5.1.3 4SC AG Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.2 Acetylon Pharmaceuticals Inc.
5.2.1 Acetylon Pharmaceuticals Inc. Company Profile
5.2.2 Acetylon Pharmaceuticals Inc. Histone Deacetylase 1 Product Specification
5.2.3 Acetylon Pharmaceuticals Inc. Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.3 Chipscreen Biosciences Ltd
5.3.1 Chipscreen Biosciences Ltd Company Profile
5.3.2 Chipscreen Biosciences Ltd Histone Deacetylase 1 Product Specification
5.3.3 Chipscreen Biosciences Ltd Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.4 Curis Inc.
5.4.1 Curis Inc. Company Profile
5.4.2 Curis Inc. Histone Deacetylase 1 Product Specification
5.4.3 Curis Inc. Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.5 GlaxoSmithKline Plc
5.5.1 GlaxoSmithKline Plc Company Profile
5.5.2 GlaxoSmithKline Plc Histone Deacetylase 1 Product Specification
5.5.3 GlaxoSmithKline Plc Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.6 HitGen LTD
5.6.1 HitGen LTD Company Profile
5.6.2 HitGen LTD Histone Deacetylase 1 Product Specification
5.6.3 HitGen LTD Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.7 IRBM Science Park SpA
5.7.1 IRBM Science Park SpA Company Profile
5.7.2 IRBM Science Park SpA Histone Deacetylase 1 Product Specification
5.7.3 IRBM Science Park SpA Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.8 Italfarmaco S.p.A.
5.8.1 Italfarmaco S.p.A. Company Profile
5.8.2 Italfarmaco S.p.A. Histone Deacetylase 1 Product Specification
5.8.3 Italfarmaco S.p.A. Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.9 MEI Pharma Inc.
5.9.1 MEI Pharma Inc. Company Profile
5.9.2 MEI Pharma Inc. Histone Deacetylase 1 Product Specification
5.9.3 MEI Pharma Inc. Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.10 Merck & Co. Inc.
5.10.1 Merck & Co. Inc. Company Profile
5.10.2 Merck & Co. Inc. Histone Deacetylase 1 Product Specification
5.10.3 Merck & Co. Inc. Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.11 Mirati Therapeutics Inc.
5.11.1 Mirati Therapeutics Inc. Company Profile
5.11.2 Mirati Therapeutics Inc. Histone Deacetylase 1 Product Specification
5.11.3 Mirati Therapeutics Inc. Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.12 Oncolys BioPharma Inc.
5.12.1 Oncolys BioPharma Inc. Company Profile
5.12.2 Oncolys BioPharma Inc. Histone Deacetylase 1 Product Specification
5.12.3 Oncolys BioPharma Inc. Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.13 Sigma-Tau S.p.A.
5.13.1 Sigma-Tau S.p.A. Company Profile
5.13.2 Sigma-Tau S.p.A. Histone Deacetylase 1 Product Specification
5.13.3 Sigma-Tau S.p.A. Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.14 Syndax Pharmaceuticals Inc.
5.14.1 Syndax Pharmaceuticals Inc. Company Profile
5.14.2 Syndax Pharmaceuticals Inc. Histone Deacetylase 1 Product Specification
5.14.3 Syndax Pharmaceuticals Inc. Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
5.15 TetraLogic Pharmaceuticals
5.15.1 TetraLogic Pharmaceuticals Company Profile
5.15.2 TetraLogic Pharmaceuticals Histone Deacetylase 1 Product Specification
5.15.3 TetraLogic Pharmaceuticals Histone Deacetylase 1 Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Histone Deacetylase 1 Market Size
6.2 North America Histone Deacetylase 1 Key Players in North America
6.3 North America Histone Deacetylase 1 Market Size by Type
6.4 North America Histone Deacetylase 1 Market Size by Application
7. East Asia
7.1 East Asia Histone Deacetylase 1 Market Size
7.2 East Asia Histone Deacetylase 1 Key Players in North America
7.3 East Asia Histone Deacetylase 1 Market Size by Type
7.4 East Asia Histone Deacetylase 1 Market Size by Application
8. Europe
8.1 Europe Histone Deacetylase 1 Market Size
8.2 Europe Histone Deacetylase 1 Key Players in North America
8.3 Europe Histone Deacetylase 1 Market Size by Type
8.4 Europe Histone Deacetylase 1 Market Size by Application
9. South Asia
9.1 South Asia Histone Deacetylase 1 Market Size
9.2 South Asia Histone Deacetylase 1 Key Players in North America
9.3 South Asia Histone Deacetylase 1 Market Size by Type
9.4 South Asia Histone Deacetylase 1 Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Histone Deacetylase 1 Market Size
10.2 Southeast Asia Histone Deacetylase 1 Key Players in North America
10.3 Southeast Asia Histone Deacetylase 1 Market Size by Type
10.4 Southeast Asia Histone Deacetylase 1 Market Size by Application
11. Middle East
11.1 Middle East Histone Deacetylase 1 Market Size
11.2 Middle East Histone Deacetylase 1 Key Players in North America
11.3 Middle East Histone Deacetylase 1 Market Size by Type
11.4 Middle East Histone Deacetylase 1 Market Size by Application
12. Africa
12.1 Africa Histone Deacetylase 1 Market Size
12.2 Africa Histone Deacetylase 1 Key Players in North America
12.3 Africa Histone Deacetylase 1 Market Size by Type
12.4 Africa Histone Deacetylase 1 Market Size by Application
13. Oceania
13.1 Oceania Histone Deacetylase 1 Market Size
13.2 Oceania Histone Deacetylase 1 Key Players in North America
13.3 Oceania Histone Deacetylase 1 Market Size by Type
13.4 Oceania Histone Deacetylase 1 Market Size by Application
14. South America
14.1 South America Histone Deacetylase 1 Market Size
14.2 South America Histone Deacetylase 1 Key Players in North America
14.3 South America Histone Deacetylase 1 Market Size by Type
14.4 South America Histone Deacetylase 1 Market Size by Application
15. Rest of the World
15.1 Rest of the World Histone Deacetylase 1 Market Size
15.2 Rest of the World Histone Deacetylase 1 Key Players in North America
15.3 Rest of the World Histone Deacetylase 1 Market Size by Type
15.4 Rest of the World Histone Deacetylase 1 Market Size by Application
16 Histone Deacetylase 1 Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Segmentation Analysis
By Type
· RCY-1305
· HG-3001
· CS-3158
· ACY-957
· ST-3595
· Other Pipeline Candidates
By Application
· Alopecia
· Endometrial Cancer
· Myelofibrosis
· Neurology (neurodegenerative diseases)
· Skin Cancer
· Hematological Malignancies
· Others
By Therapy Class
· Monotherapy HDAC1 Inhibitors
· Combination Therapies (HDAC1 + Immunotherapy/Targeted Therapy)
· Research & Development Applications
Regional Analysis
· North America: Leading market due to strong R&D infrastructure, high clinical trial activity, and presence of major biotech firms.
· Europe: Growth supported by government-funded research and strong pharmaceutical industry.
· Asia-Pacific: Fastest-growing region, with expanding biotech hubs in China, India, and Japan.
· South America: Moderate growth, with Brazil leading in oncology research collaborations.
· Middle East & Africa: Emerging opportunities with increasing healthcare investments and demand for advanced therapies.
Key Players
· 4SC AG
· Acetylon Pharmaceuticals Inc.
· Chipscreen Biosciences Ltd.
· Curis Inc.
· GlaxoSmithKline Plc
· HitGen Ltd.
· IRBM Science Park SpA
· Italfarmaco S.p.A.
· MEI Pharma Inc.
· Merck & Co. Inc.
· Mirati Therapeutics Inc.
· Oncolys BioPharma Inc.
· Sigma-Tau S.p.A.
· Syndax Pharmaceuticals Inc.
· TetraLogic Pharmaceuticals
